Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 106
- Registration Number
- NCT02981342
- Locations
- 🇺🇸
Illinois CancerCare, Peoria, Illinois, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Sarah Cannon Cancer Center, Nashville, Tennessee, United States
Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02978612
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 279
- Registration Number
- NCT02973737
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 406
- Registration Number
- NCT02958111
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
- Conditions
- Pancreatic CancerBreast CancerColorectal Cancer (CRC)Lung Cancer
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT02955940
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸New York Oncology Hematology Pc., Clifton Park, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
MEtronomic TrEatment Option in Advanced bReast cAncer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT02954055
- Locations
- 🇮🇹
Ospedale di Bolzano Oncologia Medica Via lorenz Bohler 5, Bolzano, Italy
🇮🇹"Antonio Perrino" Division of Medical Oncology Strada Statale 7 APPIA, Brindisi, Italy
🇮🇹IRST IRCCS Division of medical oncology Via Maroncelli 40, Meldola, Italy
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
- Conditions
- Esophageal CancerGastric Cancer
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02954536
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
- Conditions
- Rectal AdenocarcinomaRectal Cancer
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02935309
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 673
- Registration Number
- NCT02934529
- Locations
- 🇩🇪
Klinikum der Universitaet Muenchen - Campus Grosshadern, Munich, Germany
Multicentric Randomised Trial for Resectable Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Drug: DocetaxelDrug: OxaliplatinRadiation: radiotherapy of gastric cancerDrug: CapecitabineDrug: CarboplatinProcedure: gastrectomyDrug: Paclitaxel
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 207
- Registration Number
- NCT02931890
- Locations
- 🇳🇱
Radiotherapeutisch Instituut Friesland, Leeuwarden, Friesland, Netherlands
🇳🇱Catharina Ziekenhuis, Eindhoven, Noord Brabant, Netherlands
🇳🇱Maxima Medisch Centrum, Veldhoven, Noord Brabant, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.